Legend Biotech Corporation
LEGN
Rank in Stocks
#4443
Legend Biotech Corporation, through its subsidiaries, operates as a... Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Share Price
$19.00
Market Cap
$3.51B
Change (1 day)
1.88%
Change (1 year)
-42.27%
Country
US
Trade Legend Biotech Corporation (LEGN)
Category
Healthcare
P/E ratio for Legend Biotech Corporation (LEGN)
P/E ratio as of October 2026 TTM: -38.08
According to Legend Biotech Corporation latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -38.08. At the end of 2023 the company had a P/E ratio of -10.22.
P/E ratio history for Legend Biotech Corporation from 2017 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | -38.08 | 126.53% |
| 2024 | -16.81 | 64.41% |
| 2023 | -10.22 | 14.93% |
| 2022 | -8.89 | 4.64% |
| 2021 | -8.50 | 55.05% |
| 2020 | -5.48 | -70.15% |
| 2019 | -18.37 | -97.24% |
| 2018 | -664.51 | -354.83% |
| 2017 | 260.77 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | -175.58% |
US
|
|
| -28.36 | -25.53% |
US
|
|
| -24.57 | -35.49% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -179.65% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.